When Gal-1 immunostaining was classified as positive/negative, only five (5.15%) of the 97 cases (Figure 2B), did not exhibit the same level of Gal-1 expression in the primary tumor and matching metastatic lymph node tissues; the respective levels of non-concordance for E-cadherin and vimentin were 4.12% (4/97) and 3.10% (3/97), respectively. The gene discussed is CDH1; the disease is neoplasm.